| |
| |
| Exchange: |
OTC Bulletin Board |
| Security
Type: |
Common |
| Shares
Out: |
173,983,000 |
| Market
Cap: |
6.26(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$0.035 - $5.81 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Drug Delivery |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Adamis Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products in therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. Co.'s products and product candidates in the allergy, respiratory, and opioid overdose markets include: SYMJEPI™ (epinephrine) Injection 0.3mg for use in the emergency treatment of acute allergic reactions, including anaphylaxis; SYMJEPI (epinephrine) Injection 0.15mg for use in the treatment of anaphylaxis; ZIMHI™ (naloxone HCL Injection, USP) five mg/0.5 mL for the treatment of opioid overdose; and Tempol, an investigational drug. Co. also has a microbicide product candidate, named C31G.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Carlo Dennis J Phd |
President & CEO |
• • – |
2019-02-21 |
4 |
OE |
$0.00 |
$0 |
D/D |
27,822 |
388,883 |
|
- |
|
| Carlo Dennis J Phd |
President & CEO |
• • – |
2019-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
347,165 |
361,061 |
|
- |
|
| Hopkins Robert O |
Chief Financial Officer |
• – – |
2019-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
277,732 |
334,549 |
|
- |
|
| Daniels Karen K. |
VP of Operations |
• – – |
2019-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
173,583 |
179,944 |
|
- |
|
| Moss Ronald B. |
Chief Medical Officer |
• – – |
2019-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
277,732 |
277,732 |
|
- |
|
| Marguglio David J. |
Sr VP of Business Development |
• • – |
2019-01-30 |
4 |
A |
$0.00 |
$0 |
D/D |
277,732 |
378,755 |
|
- |
|
| Carlo Dennis J Phd |
President & CEO |
• • – |
2016-12-29 |
5 |
GD |
$0.00 |
$0 |
I/I |
25,000 |
333,709 |
|
- |
|
| Marguglio David J. |
SR. VP of Corporate Devel. |
• • – |
2016-06-02 |
4 |
AS |
$9.00 |
$6,301 |
D/D |
(700) |
101,527 |
|
- |
|
| Denby William C |
Director |
– • – |
2016-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
102,500 |
|
- |
|
| Williams Richard C |
Director |
– • – |
2016-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
150,000 |
189,918 |
|
- |
|
| Rothermel Robert B |
Director |
– • – |
2016-05-25 |
4 |
A |
$0.00 |
$0 |
D/D |
100,000 |
127,000 |
|
- |
|
| Marguglio David J. |
SR VP OF CORPORATE DEVELOPMENT |
• • – |
2016-05-16 |
4 |
AS |
$8.08 |
$32,339 |
D/D |
(4,000) |
102,227 |
|
- |
|
| Marguglio David J. |
SR VP OF CORPORATE DEVELOPMENT |
• • – |
2016-05-09 |
4/A |
AS |
$10.00 |
$60,000 |
D/D |
(6,000) |
106,227 |
|
- |
|
| Marguglio David J. |
SR VP of Corporate Development |
• • – |
2016-05-09 |
4 |
AS |
$10.00 |
$48,600 |
D/D |
(4,860) |
106,227 |
|
- |
|
| Marguglio David J. |
SR VP of Corporate Development |
• • – |
2016-05-04 |
4 |
AS |
$9.17 |
$44,577 |
D/D |
(4,860) |
112,227 |
|
- |
|
| Marguglio David J. |
SR VP of Corporate Development |
• • – |
2016-04-14 |
4 |
AS |
$7.52 |
$90,216 |
D/D |
(12,000) |
118,227 |
|
- |
|
| Glover Eddie Wabern |
CEO of U.S. Compounding, Inc. |
• – – |
2016-04-13 |
4 |
A |
$0.00 |
$0 |
D/D |
866,666 |
866,666 |
|
- |
|
| Marguglio David J. |
Senior Vice President |
• • – |
2015-12-30 |
5 |
GD |
$0.00 |
$0 |
D/D |
9,000 |
130,227 |
|
- |
|
| Rothermel Robert B |
Director |
– • – |
2015-08-14 |
4 |
B |
$3.40 |
$6,800 |
D/D |
2,000 |
27,000 |
2.39 |
- |
|
| Williams Richard C |
Director |
– • – |
2015-08-13 |
4 |
B |
$3.26 |
$31,930 |
D/D |
9,800 |
39,918 |
2.39 |
- |
|
| Rothermel Robert B |
Director |
– • – |
2015-08-13 |
4 |
B |
$3.30 |
$16,494 |
D/D |
5,000 |
25,000 |
2.39 |
- |
|
| Marguglio David J. |
Sr VP of Business Development |
• • – |
2015-04-20 |
4 |
AS |
$5.00 |
$1,000 |
D/D |
(200) |
140,323 |
|
- |
|
| Marguglio David J. |
Sr VP of Business Development |
• • – |
2015-04-17 |
4 |
AS |
$5.01 |
$501 |
D/D |
(100) |
140,523 |
|
- |
|
| Marguglio David J. |
Sr VP of Business Development |
• • – |
2015-04-16 |
4 |
AS |
$5.00 |
$3,501 |
D/D |
(700) |
140,623 |
|
- |
|
| Marguglio David J. |
Sr VP of Business Development |
• • – |
2015-04-14 |
4 |
AS |
$5.00 |
$500 |
D/D |
(100) |
141,323 |
|
- |
|
212 Records found
|
|
Page 4 of 9 |
|
|
